Trial Profile
A phase II trial of Avastin (bevacizumab) in patients with metastatic papillary renal cell carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Feb 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
- 19 Jun 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 16 Apr 2012 Actual initiation date changed from Dec 2007 to Feb 2008 as reported by ClinicalTrials.gov.